Le Lézard
Classified in: Ebola virus, Health
Subjects: TDS, FVT

Tru-D SmartUVC to Attend and Exhibit at IDWeek 2017

SAN DIEGO, Sept. 26, 2017 /PRNewswire/ -- The first and only UV disinfection robot validated by a CDC-funded randomized clinical trial, Tru-D SmartUVC will attend and exhibit at IDWeek, October 4-8, 2017 in San Diego, California. Tru-D invites IDWeek attendees to its booth #647 to learn how its technology provides thorough room disinfection, reduces the risk of hospital-acquired infections (HAIs) and makes health care facilities cleaner and safer for patients and staff.

IDWeek is the combined annual meeting of the IDSA, SHEA, HIVMA and PIDS, where infectious disease professionals are able to meet, share experiences and collaborate for the improvement of patient care and public health. Geared toward health care professionals in infectious diseases and health care epidemiology and prevention, the conference is critical for those who want to stay current in the latest trends and technologies for excellence in patient care.

"Tru-D's technology has been validated by more than a dozen third-party studies to show that it is capable of providing thorough room disinfection from one position in the room," said Chuck Dunn, CEO and President of Tru-D SmartUVC. "The pioneer of the UV disinfection space, Tru-D continues to drive innovation and acceptance of UV disinfection technology to help keep health care environments safer for the next patient who enters a room."

An automated, no-touch disinfection robot, Tru-D is brought in to a room after the environmental services (ES) staff cleans using traditional methods. Tru-D then operates from one position in the room and administers one cycle of UVC light, destroying up to 99.9 percent of harmful pathogens that can remain behind such as C. diff, MRSA, MERS, VRE, Ebola and many more. Once the cycle is finished, Tru-D alerts the operator via audio and/or text message that disinfection is complete, and Tru-D can be moved to the next room. Tru-D also delivers disinfection data to a secure myTru-D portal, allowing for real time documentation of the disinfection process, putting critical data directly in the hands of operators and administrators.

Tru-D was the only device of its kind selected for the first randomized clinical trial on UVC disinfection because of its Sensor360 technology that precisely measures the proper UV dose needed for every room, eliminating any chance for human error in the disinfection process. Results of the CDC-funded Benefits of Enhanced Terminal Room Disinfection (BETR-D) study proved that enhanced disinfection strategies that utilized Tru-D reduced the risk of acquisition and infection of four major superbugs by a cumulative 30 percent among patients who entered the same room.

Tru-D invites attendees to its booth #647 to learn more about how it reduces the risk of infections and improves patient outcomes. For more information, visit Tru-D.com.

About Tru-D SmartUVC
Only Tru-D delivers an automated, measured dose of UVC light to consistently disinfect an entire room during a single cycle. Operating from a single position in the room, Tru-D ensures significant pathogen reduction in direct and shadowed areas. Validated by more than a dozen independent studies, Tru-D's automated, measured dosing capabilities and real-time usage-tracking features make it one of the most advanced UV disinfection systems available.

Christin Yates                                  
Public Relations                             
Tru-D SmartUVC                            


These press releases may also interest you

10 aoû 2018
The "Animal Health Market Size, Share & Trends Analysis Report By Animal Type, By Product (Feed Additives, Pharmaceuticals, Vaccines, Diagnostics), By Distribution Channel, By End-use, And Segment Forecasts, 2018 - 2025" report has been added to...

8 aoû 2018
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal first quarter ended June 30, 2018. First Quarter Financial Results At June 30, 2018, the Company...

8 aoû 2018
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and...

7 aoû 2018
NanoViricides, Inc. (the "Company") reports that its anti-Shingles drug candidates were effective in ameliorating pain sensations in an animal model of abnormal pain.  A characteristic excruciating pain is a debilitating pathology of shingles...

2 aoû 2018
The International AIDS Vaccine Initiative (IAVI) today announced that it has entered into a non-exclusive license agreement with the Public Health Agency of Canada (PHAC) toward advancing development, regulatory approval, and supply of a new vaccine...

2 aoû 2018
Global in vitro diagnostic vendors and the laboratory professionals that make up their customers made the fight against anti-microbial resistance (AMR) a key focus of the American Association for Clinical Chemistry (AACC) meeting in Chicago, IL this...

News published on 26 september 2017 at 08:30 and distributed by: